Integra Lifesciences (NASDAQ:IART) Releases FY20 Earnings Guidance

Share on StockTwits

Integra Lifesciences (NASDAQ:IART) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $3.00-3.05 for the period, compared to the Thomson Reuters consensus estimate of $3.00. The company issued revenue guidance of $1.55-1.57 billion, compared to the consensus revenue estimate of $1.59 billion.Integra Lifesciences also updated its FY 2020
Pre-Market guidance to 3.00-3.05 EPS.

Shares of IART stock opened at $59.27 on Friday. Integra Lifesciences has a 52-week low of $46.07 and a 52-week high of $65.09. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.92 and a current ratio of 2.92. The firm has a market capitalization of $5.20 billion, a PE ratio of 22.08, a PEG ratio of 1.56 and a beta of 1.14. The stock has a fifty day simple moving average of $57.66 and a two-hundred day simple moving average of $59.49.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, February 19th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Integra Lifesciences had a return on equity of 16.94% and a net margin of 3.31%. The business had revenue of $395.13 million during the quarter, compared to analyst estimates of $397.51 million. During the same quarter in the prior year, the business posted $0.65 EPS. Integra Lifesciences’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, sell-side analysts forecast that Integra Lifesciences will post 3.02 EPS for the current fiscal year.

IART has been the subject of a number of analyst reports. SunTrust Banks assumed coverage on Integra Lifesciences in a research note on Friday, January 3rd. They issued a buy rating and a $56.00 price target for the company. Zacks Investment Research raised shares of Integra Lifesciences from a sell rating to a hold rating and set a $64.00 price objective for the company in a report on Friday. Wells Fargo & Co set a $62.00 price objective on shares of Integra Lifesciences and gave the company a hold rating in a report on Friday, October 25th. Piper Sandler downgraded shares of Integra Lifesciences from an overweight rating to a neutral rating and dropped their price objective for the company from $59.00 to $58.00 in a report on Tuesday, January 7th. Finally, Royal Bank of Canada set a $62.00 price objective on shares of Integra Lifesciences and gave the company a hold rating in a report on Friday, October 25th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $63.18.

In related news, VP Eric Schwartz sold 4,007 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $62.25, for a total value of $249,435.75. Also, major shareholder Richard E. Caruso sold 491,205 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $59.42, for a total transaction of $29,187,401.10. Following the completion of the transaction, the insider now directly owns 134,134 shares of the company’s stock, valued at approximately $7,970,242.28. The disclosure for this sale can be found here. 4.50% of the stock is owned by corporate insiders.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.